Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo
Xinhong Su, Renwei Luo, Shi‐Fan Ruan, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1257-1259
Closed Access | Times Cited: 21

Showing 21 citing articles:

Management of the refractory vitiligo patient: current therapeutic strategies and future options
Xinju Wang, Wei Wu, Jianru Chen, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 8
Vitiligo: Pathogenesis and New and Emerging Treatments
Javier Pérez-Bootello, Ruth Cova‐Martín, Jorge Naharro‐Rodríguez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17306-17306
Open Access | Times Cited: 17
A prospective observational study of oral abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo
Zhongyi Xu, Yijie Xuan, Yiyi Li, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 3, pp. 590-592
Closed Access | Times Cited: 5
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid‐resistant vitiligo: A prospective case series
Yijian Zhu, Zhengzhou Shi, Zhongyi Xu, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 5
Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications
Marcelina Kądziela, Magdalena Kutwin, Paulina Karp, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4919-4919
Open Access | Times Cited: 4
Knowledge, attitude, and practice toward vitiligo among vitiligo patients: a mediation analysis
Hua Feng, Xiulian Xu, Shu-Zhen Qi, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Upadacitinib monotherapy in vitiligo associated with atopic dermatitis: killing two birds with one stone
Lina Maria Magnanimi, Andrea De Berardinis, Maria Esposito, et al.
Case Reports in Dermatology (2025) Vol. 17, Iss. 1, pp. 91-95
Open Access
Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials
Xinhong Su, Yanghang Ou, Shi‐Fan Ruan, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Emerging Therapeutic Innovations for Vitiligo Treatment
Weiran Li, Penghao Dong, Guanhua Zhang, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 191-191
Open Access
A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment
Wenting Hu, Cheng Cao, Yujie Zheng, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Open Access
Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review
Hyun Jeong Ju, Jung Min Bae
Dermatology (2024) Vol. 240, Iss. 3, pp. 474-486
Open Access | Times Cited: 3
New and Upcoming Drugs for the Treatment of Vitiligo
Seol Hwa Seong, Sang Ho Oh
Annals of Dermatology (2024) Vol. 36, Iss. 4, pp. 197-197
Open Access | Times Cited: 3
Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics
Valentina Pala, Simone Ribero, Pietro Quaglino, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7486-7486
Open Access | Times Cited: 7
Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders
Mutong Zhao, Yi Zhuang, Yuan Liang, et al.
Clinical & Experimental Allergy (2024) Vol. 54, Iss. 9, pp. 694-696
Closed Access | Times Cited: 2
New Therapeutic Targets in Vitiligo
Marcelina Kądziela, Magdalena Kutwin, Paulina Karp, et al.
(2024)
Open Access | Times Cited: 1
Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
Yuzhu Mu, Ting Pan, Ling‐Ling Chen
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 1789-1792
Open Access | Times Cited: 1
JAK Inhibitors in Immune Regulation and Treatment of Vitiligo
Kewei Liu, Linyi Zhou, Meihui Shi, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 80, pp. 87-96
Closed Access | Times Cited: 1
Ritlecitinib rescues exacerbated vitiligo during the JAK1 inhibitor therapy: More than a coincidence?
Zequn Tong, Zhenlan Wu, Xueting Zeng, et al.
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-3
Open Access
Low‐Dose Baricitinib Plus Narrow‐Band Ultraviolet B for the Treatment of Progressive Non‐Segmental Vitiligo: A Prospective, Controlled, Open‐Label Study
Zhonghui Hu, Lu Lu, Jindi Feng, et al.
Pigment Cell & Melanoma Research (2024)
Open Access
Upadacitinib in dermatology: ‘Killing’ several diseases with one stone
Riccardo Balestri, Michela Magnano, Tommaso Ioris, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 8
Closed Access
Off-Label Uses of Upadacitinib
S. Abu Amara, Ariana Sapoznik, Sophie Guénin, et al.
SKIN The Journal of Cutaneous Medicine (2024) Vol. 8, Iss. 4, pp. 1614-1643
Open Access
Repigmentation in non-segmental vitiligo using the Janus kinase inhibitor upadacitinib, a retrospective case series
Jing Zhu, Lingling Luo, Youming Guo, et al.
Archives of Dermatological Research (2024) Vol. 317, Iss. 1
Closed Access
Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
Fan Huang, Dingyuan Hu, Huaying Fan, et al.
Clinical Pharmacology & Therapeutics (2024)
Open Access
Page 1

Scroll to top